News | August 07, 2024
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Subscribe To Our Newsletter & Stay Updated
